Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6958
+0.05588.72%
Volume:1.92M
Turnover:1.32M
Market Cap:155.86M
PE:-1.30
High:0.7089
Open:0.6575
Low:0.6500
Close:0.6400
52wk High:2.35
52wk Low:0.5316
Shares:224.00M
Float Shares:223.00M
Volume Ratio:2.48
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5333
EPS(LYR):-0.5922
ROE:-121.86%
ROA:-47.91%
PB:2.25
PE(LYR):-1.17

Loading ...

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)

TIPRANKS
·
May 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 16

Analyst Reiterates Buy on Positive TN-401 RIDGE-1 Data Despite Cutting Price Target from $19 to $3

TIPRANKS
·
May 15

Tenaya Shares Rise on Positive Data From ARVC Study

Dow Jones
·
May 15

Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401

TIPRANKS
·
May 15

Tenaya Therapeutics Inc - All Patients Achieve Mean 64% Decrease in Daily Pvc Count With Tn-401

THOMSON REUTERS
·
May 15

Tenaya Therapeutics Inc - Tn-401 Well Tolerated at 3E13 Vg/Kg and 6E13 Vg/Kg Doses

THOMSON REUTERS
·
May 15

Positive Interim Data From Cohorts 1 and 2 of Tenaya’s Ridge™-1 Phase 1B/2 Clinical Trial of Tn-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults With Pkp2-Associated Arvc

THOMSON REUTERS
·
May 15

Tenaya Therapeutics Inc - Tn-401 Adverse Events Were Asymptomatic and Self-Resolved or Responded to Treatment

THOMSON REUTERS
·
May 15

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

GlobeNewswire
·
May 15

Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
May 09

Tenaya Therapeutics: Buy Rating Reiterated on Upcoming Gene Therapy Catalysts and Unchanged $5 Price Target

TIPRANKS
·
May 07

Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate

Benzinga Earnings
·
May 07

Tenaya Therapeutics Q1 net loss widens, misses analyst expectations

Reuters
·
May 07

BRIEF-Tenaya Therapeutics Q1 Net Income USD -19.272 Million

Reuters
·
May 07

Tenaya Therapeutics Q1 Operating Income USD -20.065 Million

THOMSON REUTERS
·
May 07

Tenaya Therapeutics Q1 Pretax Profit USD -19.272 Million

THOMSON REUTERS
·
May 07

Press Release: Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 07

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
May 06